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Abstract
OBJECTIVES: The effect of 1,25-dihydroxycholecalciferol (calcitriol, vitamin D3) with a low-calcium diet on the acute lung allograft re-
jection in a rat unilateral left lung transplantation model was evaluated.
METHODS: Three transplantation groups were studied (n = 5, male Brown-Norway to Fischer F344, 235 ± 15 g body weight): calcitriol
and low-calcium diet, low-calcium diet and normal diet. Calcitriol (4 μg/kg/day) was injected intraperitoneally for 5 days, starting from
the day of transplantation. In addition, two non-transplantation groups were compared: (n = 3, Brown-Norway) to measure the level of
cytokines, and Fischer F344 receiving calcitriol and a low-calcium diet to measure the serum calcium level. The recipients of transplant-
ation were killed on Day 5 post-transplant. The contralateral right main bronchus and the pulmonary artery were occluded for 5 min
and blood was drawn for the blood gas analysis, and the grafts were assessed for histology (International Society for Heart and Lung
Transplantation 1996/rank scale). Lung levels of interleukin (IL)-2, IL-6, IL-12 and tumour necrosis factor-α (TNF-α) were assessed within
the calcitriol and low-calcium diet, low-calcium diet and Brown-Norway groups. The serum calcium level was assessed in the Fischer
F344 group. An analysis of variance with Tukey’s post hoc test was used to compare the arterial blood oxygen pressure and the lung
cytokine expression between groups. A non-parametric Kruskal–Wallis test followed by the Siegel and Castellan post hoc test was used
to assess the differences between the groups according to the lung graft rejection grading. Student’s paired t-test was used to compare
the serum calcium level.
RESULTS: The arterial PaO2 was signiﬁcantly higher in the calcitriol and the low-calcium diet groups when compared with low-calcium
diet or normal diet groups (356 ± 72 mmHg; P < 0.05 vs other groups). The arterial and bronchial rejection observed in calcitriol and
low-calcium diet group was signiﬁcantly milder than in the low-calcium diet or normal diet groups (A1-2, B1-2; P < 0.05 vs other
groups). IL-2 and IL-6 levels were signiﬁcantly higher in low-calcium diet vs calcitriol and low-calcium diet and Brown-Norway groups.
IL-12 and TNF-α did not differ among the groups. There was no signiﬁcant difference in serum calcium level before and after the treat-
ment in the Fischer F344 group.
CONCLUSIONS: Calcitriol with a low-calcium diet treatment improves lung function, reduces lung allograft acute rejection, decreases
IL-2 and IL-6 allograft expression and does not change the serum calcium level signiﬁcantly.
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INTRODUCTION
Lung transplantation is an established therapeutic option in the
end-stage of pulmonary disease. However, acute rejection limits
the short-term survival of lung transplant recipients. In addition,
the high level of immunosuppression, for example, compared
with kidney recipients, needed in these patients causes a number
of unwanted side effects of the different drugs. Therefore, sub-
stances that may attenuate the side effects are needed.
1,25-Dihydroxycholecalciferol (1,25-dihydroxyvitamin D3, cal-
citriol) has been studied as an immunosuppressant in recent
years. The proﬁle of side effects of this substance seems to be
more favourable than the drugs currently used as standard
medication following organ transplantation. It has been shown
in vivo and in vitro that calcitriol strongly inﬂuences the immune
system [1]. A number of mechanisms have been described that
may explain the immunosuppressive properties of calcitriol and
its analogues. It shifts the differentiation of the Th0 lymphocytes
towards Th2 and inhibits the generation of Th1 lymphocytes [2],
increases the suppressor activity of CD8+ and CD4+ effectors
function. Furthermore, calcitriol inhibits the immunoglobulin
G2a production by B cells, reduces the major histocompatibility
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complex (MHC) II expression, prevents the development of cyto-
toxic effects and inhibits the differentiation and maturation of
dendritic cells [3]. An increased expression of MHC class II anti-
gens is observed during the acute rejection in lung allotransplan-
tation in Mongrel dogs [4]. Calcitriol also induces apoptosis in
peripheral mononuclear cells and inhibits pathological angiogen-
esis [5]. In this study, we evaluated the effect of calcitriol on the
acute rejection in one major and one minor immunologically




A model of allogeneic left lung allotransplantation in rats with
one major and one minor MHC mismatch (donor:
Brown-Norway; recipient: Fischer F344; obtained from RCC Ltd.,
Biotechnology & Animal Breeding Division, Füllinsdorf,
Switzerland) was used. All the animals were male. Five animal
groups were studied—three transplantation groups (n = 5, calci-
triol and low-calcium diet, low-calcium diet and normal diet),
and two non-transplantation groups (n = 3, Brown-Norway and
Fischer F344). Recipients in the calcitriol and low-calcium diet
group received 4 μg/kg/day calcitriol by intraperitoneal injection
for 5 days post-transplant and were put on a low-calcium diet
for 12 days (7 days before and 5 days after transplantation).
Recipients in the low-calcium diet group received a low-calcium
diet for 12 days (7 days before and 5 days after transplantation).
The normal diet group recipients were put on a normal diet
before and after transplantation. The Brown-Norway group imi-
tating donors served as controls for the measurement of cyto-
kines and consisted of male Brown-Norway rats. The Fischer
F344 group imitating recipients served to measure the serum
calcium level before and after calcitriol injection for 5 days and a
low-calcium diet for 12 days treatment and consisted of male
Fischer F344 rats.
A low-calcium diet was fed to the calcitriol and low-calcium
diet group and the animals of the Fischer F344 group from Day 0
to Day 12 throughout the experiment. On Day 7, orthotropic
single left lung transplantations were performed from
Brown-Norway to Fischer F344 rats of the transplantation groups,
using the cuff technique [6] for the vessel anastomoses and a con-
ventional running over-and-over suture for the bronchial anasto-
mosis. Calcitriol (4 μg/kg/day i.p.) was given to the calcitriol and
low-calcium diet group and the Fischer F344 animals from Day 7
of the experiment and continued until the animals were killed.
The low 0.02% calcium diet was provided by the University of
Wisconsin, Madison, WI, USA. Calcitriol (Rocaltrol®) and 10 ml
solution, 1 μg/ml was provided by Roche, Basel, Switzerland.
All the animals received care in compliance with the
‘Principles of Laboratory animal care’ NIH publication Vol. 25,
No. 28 revised 1996. The protocol was approved by the local
animal study committee.
Operative procedure and measurements
Donor. The animal was anaesthetized in a glass chamber by
allowing it to inhale 4% Halothane (SIGMA®, Buchs, Switzerland).
Thiopental (Penthotal, Abbott AG) and a dose of 50 mg/kg was
injected intraperitoneally. Heparin (Liquemin, Roche Pharma,
Switzerland) was administered through a peripheral vein (500
IU/kg). A tracheotomy was performed, and the animal was
ventilated using a 14-gauge i.v. catheter (Insyte®, Madrid, Spain),
with 100% oxygen, f = 100/min, tidal volume (TV) = 10 ml/kg, and
by a Harvard Rodent Ventilator (model 683, Harvard Apparatus,
South Natick, MA, USA). After cutting the inferior vena cava and
the left appendix of the heart, a small silicon hose was inserted
into the main pulmonary artery (PA) via an incision in the right
ventricle. Both lungs were ﬂushed with 20 ml of a low-potassium
dextrane solution (Perfadex®, Medisan Pharmaceutics, Uppsala,
Sweden) at a pressure of 20 cm H2O. The trachea was then tied
at the end-inspiratory position. The heart–lung block was
removed and the left lung was separated ex vivo from the heart
and the right lung. Twenty-four gauge cuffs were placed around
the PA and vein; the vessels were everted and tied onto the cuff
and fastened with 8-0 monoﬁlament suture (Surgipro, USSC,
USA). The lung was stored at 10°C in an low potassium dextrane
solution, until implantation.
Recipient. The recipient was anaesthetized in a glass chamber
by allowing it to breathe 2% Halothane (SIGMA®), intubated and
anaesthesia was maintained with Halothane. A left thoracotomy
in the fourth intercostal space was performed. The neurovascular
clips were put onto the left PA and left pulmonary vein (PV). The
left main native bronchus was ligated with a 6-0 polyﬁlament
suture (Sofsilk, USSC, USA) and was cut off. An incision was
made in both the PV and PA. The vessels were ﬂushed with a
heparinized saline solution. The cuffs were inserted into the
recipient’s vessels, and 6-0 polyﬁlament ligatures (Sofsilk, USSC)
were placed around the cuffs and tied. The native PA and PV
were cut off beyond the anastomosis and the native lung was
removed. A 9-0 Monosof (Tyco Healthcare, Wollerau,
Switzerland) running over-and-over continuous suture was used
for the bronchial anastomosis. The ventilation and then
retrograde perfusion followed by the antegrade perfusion of the
graft were restored by removing the clips from the left bronchus,
PV and PA, respectively. A chest drain (24Gx3/4 infusion set,
Terumo®, Belgium) was inserted into the left hemithorax and the
thoracotomy was closed with four layers of continuous sutures
(4/0 Prolene, Johnson and Johnson®). The thoracic drain was
removed after the animal restored spontaneous breathing, and
the animal was extubated.
Assessment
Arterial blood oxygen partial pressure. On Day 12, 5 days
post-transplant, the animals from the transplantation groups
were pre-anaesthetized in a glass chamber by allowing them to
inhale 4% Halothane (SIGMA®). Thiopental (Pentothal, Abbott
AG) at a dose of 50 mg/kg was injected intraperitoneally. The
animal was ventilated via tracheotomy—using Harvard Rodent
Ventilator model 683 (Harvard Apparatus) with 100% oxygen
(FiO2 = 1.0), f = 100/min, TV = 10 ml/kg. A thoracolaparotomy in
the anterior midline was performed. Microvascular clips were
put on the right main bronchus and right PA in order to
ventilate and perfuse only the isolated left lung graft. After
establishing a steady state (5 min), 300 μl of blood was aspirated
from the aortic arch to a syringe (Pico™ 50 Radiometer,
Copenhagen, Denmark) for arterial PaO2 assessment
(Radiometer ABL 700 Series, Copenhagen, Denmark).
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Subsequently, the inferior vena cava and left appendix of the
heart were incised and a small silicon hose was inserted into the
main PA via an incision in the right ventricle. The lungs were
then ﬂushed with 20 ml of 0.9% NaCl under a pressure of 20 cm
of H2O. The trachea was ligated at the end-inspiratory position
and the tracheotomy tube was removed. The heart-and-lung
block was explanted and the sample of the left grafted lung was
put in a 10% formalin solution (SIGMA®) for histological analysis,
and the rest of the graft was snap-frozen in liquid nitrogen for
cytokine analysis. In the Brown-Norway group, the left native
lung was used for the analysis of cytokines.
Rejection grading. The histological assessment of the acute
rejection of the transplantation groups was done by a trained
lung pathologist in a blinded fashion according to the Working
Formulation for the 1996 Classiﬁcation of Pulmonary Allograft
Rejection of the International Society for Heart and Lung
Transplantation (ISHLT) [7].
Lung cytokine
Quantitative reverse transcription polymerase chain
reaction. The cytokine levels were assessed in the lungs of the
calcitriol and low-calcium diet, low-calcium diet and
Brown-Norway groups. Total RNA was isolated from the frozen
lung tissue using the SV Total RNA Isolation Kit (Promega, Zurich,
Switzerland) and then 1 μg of RNA was reverse-transcribed into
cDNA (Omniscript™, Qiagen). Transcript levels for cytokines were
quantiﬁed using real-time quantitative polymerase chain reaction
(AMB Prism 7700; Perkin Elmer Applied Biosystems, Foster City,
CA, USA). Primers and probes for the cytokines were designed
using the Primer Express Software (Applied Biosystems).
6-carboxyﬂuorescein and tetramethylrhodamine were used as
reporter and quencher dyes, respectively, for labelling the probes.
Cytokine levels were normalized to 18S rRNA using a
pre-developed kit (Part # 4310875, Applied Biosystems). The
design of primers and probes is shown in Table 1.
Serum calcium level. The serum calcium level was assessed in
the non-transplantation Fischer F344 group. The animals were fed
with a low-calcium diet for 12 days. On Day 0, 500 μl of full blood
was drawn from the left external jugular vein, using a syringe
(Pico™ 50 Radiometer). The calcium concentration was measured
with a radiometer (ABL 700 Series). From Days 7 to 12, the rats
received 4 µg/kg/day calcitriol i.p. On Day 12 (the day on which
the animals were killed), another 500 μl of blood was drawn from
the vena cava inferior for the calcium level measurement.
Statistics
Analysis of variance (ANOVA) with Tukey’s post hoc test was used
to compare the arterial blood oxygen partial pressure and the
lung cytokine expression between groups. Oxygen partial pres-
sure and interleukin (IL)-6 expression were transformed logarith-
mically for this analysis to obtain normal distributions. A
non-parametric Kruskal–Wallis test followed by Siegel and
Castellan post hoc test was used to assess differences between
the groups according to the lung graft rejection grading.
Student’s paired t-test was used to compare the serum calcium
level. STATISTICA PL, version 7.1, Statsoft, Cracow was used for
the statistical analysis.
RESULTS
Characterization of experimental groups
In the three transplantation groups (n = 5, calcitriol and low-
calcium diet, low-calcium diet, normal diet), the donor and
recipient rats weighed 235 ± 15 g, with no statistical difference
between the groups. The entire transplantation procedure
(donor lung explantation, ex vivo preparation and implantation)
took 126 ± 18 min. The warm ischaemic time was 24 ± 6 min,
without any statistical difference between the groups. In the two
non-transplantation groups (n = 3, Brown-Norway, Fischer F344),
the rats were of the same weight. The operative procedures were
done by the author personally, under a stereoscopic microscope
(Olympus®, SZX12, Japan) with a magniﬁcation of 6–20 times.
Three recipients of the transplantation groups died because of
technical errors and additional transplantations were carried out
to replace these animals.
Arterial blood oxygen partial pressure
The arterial blood oxygen partial pressure was measured in all
three transplantation groups. The results are shown in Fig. 1.
ANOVA revealed the statistically highly signiﬁcant difference
among the three transplantation groups (P < 0.000001).
Inter-group comparisons between the calcitriol and low-calcium
diet group (356 ± 72 mmHg) and the low-calcium diet group (46
± 8.0 mmHg), as well as between the calcitriol and low-calcium
diet and the normal diet groups (36 ± 10.9 mmHg) are statistical-
ly signiﬁcant (P = 0.00019 for each comparison, Tukey’s post hoc
test) in contrast to the comparison between the low-calcium
diet and normal diet groups (P = 0.49).
Rejection grading
The histological assessment was done in all three transplantation
groups. The results are shown in Table 2. It demonstrates the sig-
niﬁcant difference between the calcitriol and low-calcium diet
vs normal diet group (P = 0.005 and P = 0.008 for peri-arterial A
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and peri-bronchial B inﬁltrations, respectively). Figure 2 demon-
strates the histologic slide of mildly rejected A1B1 rat lung tissue
in calcitriol and low-calcium diet group and Fig. 3 strongly
rejected A3B3 rat lung tissue in low-calcium diet and normal
diet groups. The slides are obtained from the grafts excised form
the recipient rats.
Lung cytokine expression
The cytokine levels were measured within the calcitriol and low-
calcium diet, low-calcium diet and Brown-Norway groups. The
expression of the IL-2 and IL-6 cytokines, as shown in Fig. 4, was
the strongest in the low-calcium diet group and the lowest in
the Brown-Norway group. ANOVA showed signiﬁcant differences
between groups for both IL-2 (P = 0.0051) and IL-6 (P =
0.000022). According to Tukey’s test, statistical signiﬁcance was
reached in the low-calcium diet against the calcitriol and low-
calcium diet group (P = 0.026 for IL-2 and P = 0.019 for IL-6) or
against Brown-Norway (P = 0.021 and P = 0.00019, respectively),
but the difference in calcitriol and a low-calcium diet against the
Brown-Norway group was signiﬁcant only for IL-6 (P = 0.00070)
and not for IL-2 (P = 0.92).
ANOVA showed no signiﬁcant intergroup differences for IL-12
(P = 0.68) nor tumour necrosis factor-α (TNF-α; P = 0.29).
Serum calcium level
The serum calcium level was measured in the non-
transplantation Fischer F344 group. We found no signiﬁcant dif-
ference between Day 0 (1.35 ± 0.085 mmol/l) and Day 12 (1.33 ±
0.01 mmol/l) in the rats with a low-calcium diet from Day 0 and
calcitriol treatment from Day 7 to 12 when the animals were
killed (P = 0.71). However, it should be noted that owing to a
small number of animals, the conﬁdence interval for the differ-
ence is wide (from −0.22 to +0.18 mmol/l).
DISCUSSION
In this study, we have shown that 1,25-dihydroxycholecalciferol
(calcitriol, vitamin D3) reduces acute lung allograft rejection. This
is illustrated by better graft function (higher arterial blood
oxygen pressure) and less histological damage (lower ISHLT 1996
rejection grading) in the calcitriol-treated recipients of the calci-
triol and low-calcium diet group. The high dose of calcitriol ad-
ministration combined with a low-calcium diet did not increase
serum calcium levels in the Fischer F344 group signiﬁcantly. We
did not create a control group receiving calcitriol and a normal
diet, as we were afraid of hypercalciuria, hypercalcaemia and its
sequels, such as calcium deposition in soft tissue. To our sur-
prise, we did not register any changes in the calcium level and
in future, a control group receiving calcitriol and a normal diet
Table 2: Rejection grading according to ISHLT
D3 + LCD LCD ND
Vascular A A1 (A1-A2) A3 (A2-A3) A3 (A3-A4)
Airway B B1 (B1-B2) B3 (B3) B3 (B3-B4)
P < 0.05 for: calcitriol and low-calcium diet (D3 + LCD) vs low calcium
diet (LCD), and vs normal diet (ND) in vascular and arterial rejection.
Figure 2: Histologic slide of mildly rejected A1B1 rat lung tissue in calcitriol
and low-calcium diet (D3 + LCD) group.
Figure 1: Signiﬁcant improvement of the arterial oxygen content by treatment
with calcitriol and a low-calcium diet (D3 + LCD) compared with low-calcium
(LCD) and normal diets (ND).
Figure 3: Histological slide of strongly rejected A3B3 rat lung tissue in the
low-calcium diet (LCD) and normal diet (ND) groups.
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could be used. We have also shown that calcitriol-treated, less-
rejected grafts express lower level of IL-2 and IL-6, but the IL-12
and TNF-α level remains uninﬂuenced.
Calcitriol is the active form of Vitamin D—cholecalciferol. In
mammals, cholecalciferol is hydroxylated on C-25 in the liver
and on C-1 in the kidneys. Until the late 70s, calcitriol was con-
sidered to be a regulator of calcium, phosphorus and bone me-
tabolism only. In the 80s, the immunoregulatory properties of
calcitriol have been discovered, and it has been shown that cal-
citriol suppresses T-helper-cell-mediated delayed hypersensitiv-
ity. The immunosuppressive properties of calcitriol are mediated
by cells possessing nuclear Vitamin D receptor (VDR) [8]. The
VDR is present in the cell cytoplasm and binds to the DR-3 pro-
moter region of target genes to stimulate or suppress transcrip-
tion, followed by translation of characteristic proteins. VDR
changes its three-dimensional structure after speciﬁc, i.e. calci-
triol activation. This is the key element of its action in the cell
nucleus. Many factors inﬂuence the DNA transcription into
mRNA—for example, VDR homo- or heterodimerization with
retinoid X receptor. This means that the VDR complex may enter
the nucleus and bind to its DNA. A lot of proteins may bind to
the VDR complex which increase or decrease its chromatin con-
densation, thus acting as a co-repressor or co-activator and at
the same time increasing or decreasing the target gene tran-
scription. The co-activators bind the few additional proteins,
building connections in the basic transcription mechanism.
Therefore, little changes in the three-dimensional VDR shape
caused by the activator may lead to a modulation in the protein
binding and gene transactivation. This feature of nuclear recep-
tors makes them an interesting therapeutic goal [9] . Hundreds of
genes reacting with the elements of the nuclear VDR have a
direct or indirect impact on the cell cycle, proliferation, differen-
tiation or apoptosis. Apart from calcium regulation, Vitamin D
inﬂuences physiologic and pathologic cell growth, carcinogen-
esis, immunologic and coronary vessel function [10]. VDR is a
very common protein and is present in nearly every cell of the
Figure 4: Lung cytokine expression shows a signiﬁcantly higher IL-2 and IL-6 expression in the low-calcium diet (LCD) vs calcitriol and low-calcium diet (D3 +











B. Kubisa et al. / European Journal of Cardio-Thoracic Surgery 875
mammalians. Almost 3% of the human genome can be inﬂu-
enced by the VDR [11]. VDRs are present not only in the intes-
tine, bone and kidney, but also in islet cells of the pancreas,
parathyroid gland, haematopoetic cells, promyelocytes, activated
lymphocytes, T-cells of thymus, keratinocytes of reproductive
organs and skin. It has been proved that calcitriol inhibits the
apoptosis of hepatocytes after allogeneic rat liver transplantation [12].
Calcitriol promotes Th0 differentiation into Th2 and, at the
same time, inhibits differentiation into the Th1 subpopulation.
That decreases the level of Th1-produced cytokines IL-2 and
TNF-α. The lower concentration of these two cytokines
decreases the MHC class II antigen expression on the antigen
presenting cell (APC) surface. Calcitriol inhibits the production of
IL-12, which is among the stimuli responsible for the activation
of natural killer (NK) cells. Further research in the ﬁeld of auto-
immune diseases and organ transplantation were very promising.
Experimental allergic encephalomyelitis in a murine model of
multiple sclerosis has been totally or partially prevented, as well
as lupus nephritis in mice, Heymann’s nephritis [13], experimen-
tal autoimmune thyroiditis and an experimental model of
human arthritis. Furthermore, acute rejection was reduced after
the transplantation of pancreatic islets grafts in non-obese type I
diabetes mice, and the mean survival time of non-vascularized
neonatal heart transplants in rats and mice was prolonged. The
VDR agonists can help us to treat ischaemic heart disease, as
there is a higher risk of developing this condition by the patients
with a lower serum level of Vitamin D or calcitriol [14].
The anti-proliferative effect of calcitriol on skin keratinocytes
has been used in the treatment of dermatological disorders, e.g.
psoriasis. Calcitriol stimulates the cell to differentiate into the
ﬁnal form and then to stop further proliferation (e.g. promyelo-
cytes into monocytes). In other words, it causes the terminal dif-
ferentiation in cells possessing VDR.
Calcitriol is an agonist of VDR and inﬂuences dendritic cells
possessing the function of APCs. Activated VDR induces im-
munological tolerance in the APC and causes its maturation,
though there are papers stating opposite, claiming that calcitriol
inhibits APC maturation and differentiation, decreasing the ex-
pression of co-stimulating particles [15]. Calcitriol inﬂuences the
monocytes (dendritic cells and macrophages precursors), which
activate CD4+ lymphocytes in such a way that the interferon-γ
level is decreased and IL-10 level is increased [16].
In allotransplantation, NK cells recognize the decrease of
MHC antigens expression and mediate the target cell death by
perforine, TNF-β, gramzines and by antibody-dependent cell-
mediated cytotoxity. On the other hand, IL-2 activates CD8+ T
lymphocytes, which show cytotoxity in the context of class I
MHC antigens. Calcitriol inﬂuences not only the T-cell lympho-
kine production, but also T-cell proliferation, as it arrests the
cells in the G0/G1 transition phase. Calcitriol also blocks IL-2
transcription mediated by nuclear factor of activated T cells and
interacts with the T-cell activation cascade at a level downstream
calcineurin [17].
In this study, the graft function of the calcitriol and low-
calcium diet group was highly improved in comparison with the
untreated controls of the low-calcium and normal diet groups.
These results were correlated with the histologicalal analysis
showing much higher rejection in control grafts of the low-
calcium and normal diet groups.
In our experiment, four key cytokines were chosen to evaluate
the effect of calcitriol. In this study, we were able to show
reduced IL-2, but not IL-12 expression. IL-6 has been shown to
be the lung ischaemia-reperfusion injury [18] and kidney acute
rejection marker [19], and IL-2 was found to be an acute rejec-
tion marker in the heart transplant [20]. In our study, we con-
ﬁrmed that the highest expression of IL-6 was observed in the
severely rejected grafts (low-calcium diet group), reduced IL-6
was noted in calcitriol-treated grafts (calcitriol and low-calcium
diet group) and signiﬁcantly lower IL-6 was found in normal
lung tissue (Brown-Norway group). IL-6 was the most sensitive
cytokine differentiating signiﬁcantly all three assessed groups
from each other. TNF-α and IL-12 expression, however, was not
altered by calcitriol and low-calcium diet treatment. The cyto-
kine expression was measured in the lung tissue homogenate,
though it would also be interesting to check it in the bronchoal-
veolar lavage ﬂuid. We did not perform it in order not to blur
the lung tissue homogenate measurements. We think that either
of these two could be evaluated in one recipient, but not both
simultaneously.
Nowadays, to diagnose lung allograft acute rejection, the lung
tissue sample has to be obtained or serum cytokine level has to
be assessed. But it is also possible to suspect acute cellular rejec-
tion by measuring the uric acid serum level, as it was shown in
the heart transplantation rejection by patients [21] and this can
be used for rejection monitoring purposes in future.
In conclusion, calcitriol can be considered as a new experi-
mental immunosuppressant, improving graft function markedly.
Calcitriol inhibits the expression of IL-2, and it is consistent with
the results of other studies [22], where acute rejection of the rat
allografted lung increases the IL-2 mRNA level in the lung tissue.
1,25-Dihydroxycholecalciferol inhibits the expression of IL-6, but
does not inﬂuence IL-12 and TNF-α level in lung allografts. The
lack of acute rejection inﬂuencing TNF-α level was observed by
others [23]. The calcitriol dose in the present experiment was
high (4 μg/kg/day) and we have previously proved that 0.5 μg/
kg/day was a sub-therapeutic dose and does not affect acute re-
jection alone [24].
There are some limitations in this study. The serum calcium
level could not be measured in the transplantation groups, as
the blood for the partial oxygen pressure measurement has to
be heparinized and it makes the calcium assessment improper.
Also, the rat blood sample size limits the number of assess-
ments possible. In future, the experiment could therefore be
repeated on the bigger animal model. In this study, we have
used the older version of ISHLT rejection grading. In the new
issue coming from 2007 [25], previous B1 and B2 stages are
combined into B1R and B3 and B4 into B2R. For statistical
reasons, it was easier to use the older, more stratiﬁed
classiﬁcation.
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